242 related articles for article (PubMed ID: 18797587)
1. [Noonan syndrome: from phenotype to growth hormone therapy].
Malaquias AC; Ferreira LV; Souza SC; Arnhold IJ; Mendonça BB; Jorge AA
Arq Bras Endocrinol Metabol; 2008 Jul; 52(5):800-8. PubMed ID: 18797587
[TBL] [Abstract][Full Text] [Related]
2. Response to growth hormone in short children with Noonan syndrome: correlation to genotype.
Binder G
Horm Res; 2009 Dec; 72 Suppl 2():52-6. PubMed ID: 20029239
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular characterization of children with Noonan syndrome and other RASopathies in Argentina.
Chinton J; Huckstadt V; Moresco A; Gravina LP; Obregon MG
Arch Argent Pediatr; 2019 Oct; 117(5):330-337. PubMed ID: 31560489
[TBL] [Abstract][Full Text] [Related]
4. Abnormal growth in noonan syndrome: the challenge of optimal therapy.
Savage MO; Padidela R; Kirk JM; Malaquias AC; Jorge AA
Pediatr Endocrinol Rev; 2009 Jun; 6 Suppl 4():523-8. PubMed ID: 19550387
[TBL] [Abstract][Full Text] [Related]
5. PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
Brasil AS; Pereira AC; Wanderley LT; Kim CA; Malaquias AC; Jorge AA; Krieger JE; Bertola DR
Genet Test Mol Biomarkers; 2010 Jun; 14(3):425-32. PubMed ID: 20578946
[TBL] [Abstract][Full Text] [Related]
6. Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype.
Ekvall S; Hagenäs L; Allanson J; Annerén G; Bondeson ML
Am J Med Genet A; 2011 Jun; 155A(6):1217-24. PubMed ID: 21548061
[TBL] [Abstract][Full Text] [Related]
7. Alterations in RAS-MAPK genes in 200 Spanish patients with Noonan and other neuro-cardio-facio-cutaneous syndromes. Genotype and cardiopathy.
Ezquieta B; Santomé JL; Carcavilla A; Guillén-Navarro E; Pérez-Aytés A; Sánchez del Pozo J; García-Miñaur S; Castillo E; Alonso M; Vendrell T; Santana A; Maroto E; Galbis L
Rev Esp Cardiol (Engl Ed); 2012 May; 65(5):447-55. PubMed ID: 22465605
[TBL] [Abstract][Full Text] [Related]
8. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11.
Noordam C; Peer PG; Francois I; De Schepper J; van den Burgt I; Otten BJ
Eur J Endocrinol; 2008 Sep; 159(3):203-8. PubMed ID: 18562489
[TBL] [Abstract][Full Text] [Related]
9. [Phenotype variability in Noonan syndrome patients with and without PTPN11 mutation].
Ferreira LV; Souza SA; Montenegro LR; Arnhold IJ; Pasqualini T; Heinrich JJ; Keselman AC; Mendonça BB; Jorge AA
Arq Bras Endocrinol Metabol; 2007 Apr; 51(3):450-6. PubMed ID: 17546245
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the PTPN11 gene in idiopathic short stature children and Noonan syndrome patients.
Ferreira LV; Souza SC; Montenegro LR; Malaquias AC; Arnhold IJ; Mendonca BB; Jorge AA
Clin Endocrinol (Oxf); 2008 Sep; 69(3):426-31. PubMed ID: 18331608
[TBL] [Abstract][Full Text] [Related]
11. PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome.
Ferreira LV; Souza SA; Arnhold IJ; Mendonca BB; Jorge AA
J Clin Endocrinol Metab; 2005 Sep; 90(9):5156-60. PubMed ID: 15956085
[TBL] [Abstract][Full Text] [Related]
12. Noonan syndrome and clinically related disorders.
Tartaglia M; Gelb BD; Zenker M
Best Pract Res Clin Endocrinol Metab; 2011 Feb; 25(1):161-79. PubMed ID: 21396583
[TBL] [Abstract][Full Text] [Related]
13. Response to growth hormone therapy in children with Noonan syndrome: correlation with or without PTPN11 gene mutation.
Choi JH; Lee BH; Jung CW; Kim YM; Jin HY; Kim JM; Kim GH; Hwang JS; Yang SW; Lee J; Yoo HW
Horm Res Paediatr; 2012; 77(6):388-93. PubMed ID: 22777296
[TBL] [Abstract][Full Text] [Related]
14. Co-occurring PTPN11 and SOS1 gene mutations in Noonan syndrome: does this predict a more severe phenotype?
Brasil AS; Malaquias AC; Wanderley LT; Kim CA; Krieger JE; Jorge AA; Pereira AC; Bertola DR
Arq Bras Endocrinol Metabol; 2010 Nov; 54(8):717-22. PubMed ID: 21340158
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular characterization of 40 patients with Noonan syndrome.
Ferrero GB; Baldassarre G; Delmonaco AG; Biamino E; Banaudi E; Carta C; Rossi C; Silengo MC
Eur J Med Genet; 2008; 51(6):566-72. PubMed ID: 18678287
[TBL] [Abstract][Full Text] [Related]
16. Congenital heart defects in Noonan syndrome: Diagnosis, management, and treatment.
Linglart L; Gelb BD
Am J Med Genet C Semin Med Genet; 2020 Mar; 184(1):73-80. PubMed ID: 32022400
[TBL] [Abstract][Full Text] [Related]
17. Expanding the genetic spectrum of Noonan syndrome.
Noordam K
Horm Res; 2007; 68 Suppl 5():24-7. PubMed ID: 18174700
[TBL] [Abstract][Full Text] [Related]
18. [RAS/MAPK signal transduction pathway and its role in the pathogenesis of Noonan syndrome].
Gos M; Leszkiewicz M; Abramowicz A
Postepy Biochem; 2012; 58(3):255-64. PubMed ID: 23373411
[TBL] [Abstract][Full Text] [Related]
19. Molecular and clinical profile of patients referred as Noonan or Noonan-like syndrome in Greece: a cohort of 86 patients.
Papadopoulos G; Papadopoulou A; Kosma K; Papadimitriou A; Papaevangelou V; Kanaka-Gantenbein C; Bountouvi E; Kitsiou-Tzeli S
Eur J Pediatr; 2022 Oct; 181(10):3691-3700. PubMed ID: 35904599
[TBL] [Abstract][Full Text] [Related]
20. Abnormal growth in noonan syndrome: genetic and endocrine features and optimal treatment.
Padidela R; Camacho-Hübner C; Attie KM; Savage MO
Horm Res; 2008; 70(3):129-36. PubMed ID: 18663312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
